ACU234 / Acumen Pharma - LARVOL DELTA

DEVELOPMENT AND CHARACTERIZATION OF NOVEL ANTIBODIES TARGETING AMYLOID BETA OLIGOMERS WITH HIGH SELECTIVITY (ADPD 2026) - "The present studies have identified three novel AβO mAbs of interest, with ACU234 being ~ 21,000-fold selective for oligomeric versus monomeric Aβ. ACU234 was also able to engage endogenous AβOs in both Tg mouse and AD brain. Further work is needed to characterize ACU234 and explore its potential to be a novel AβO-targeting mAb."

Alzheimer's Disease • CNS Disorders

Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with High Selectivity (GlobeNewswire) - "Researchers used SPR to measure antibody affinity and selectivity of these novel anti-AβO monoclonal antibodies (mAbs) for AβOs compared to monomers (Aβ1-28 and Aβ1-40). The study identified three novel AβO mAbs of interest, with ACU234 demonstrating notable selectivity – approximately 21,000-fold greater affinity for oligomeric versus monomeric Aβ. ACU234 underwent further evaluation using both in vitro and in vivo models of target engagement, including staining human brain samples from AD and controls compared to known Aβ mAbs, and injection into ARTE10 transgenic (Tg) mice to assess brain localization....Further work is needed to characterize ACU234 and explore its potential as an AβO-targeting therapeutic."

Preclinical • Alzheimer's Disease